Tested drug for solid tumors after standard treatment stopped
Part of Cancer clinical trials.
This Phase 1 study tests SB17170 in people with solid tumors that have spread or grown despite standard treatments. It looks for safety and early signs of how well the drug might work when other options have failed.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have a confirmed diagnosis of a solid cancer (by biopsy or sample), and it is locally advanced or metastatic (has spread).
- Your cancer has either not responded to the usual treatment or has become resistant, and there is no other standard treatment that fits.
- You have at least one measurable tumor spot doctors can track on scans.
- Your general functioning is good (ECOG 0 or 1, meaning you are fully active or limited in strenuous activity).
- You are expected to live at least 3 months, based on the study doctor’s judgment.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new drug (BB-1709) for people with advanced solid tumors that haven't responded to standard treatments. The goal is to see if it's safe and how well it works.
This Phase 1 trial tests BB-1705 in people with advanced or metastatic (spread) solid tumors that cannot be removed with surgery. It mainly focuses on safety and how the drug behaves in the body, and may offer an option for patients when standard treatments have not worked.
This study tests a new drug, CRB-601-01, for people with advanced solid tumors that have not responded to other treatments. The goal is to see if it is safe and can help shrink tumors.
This trial tests MPB-1734, a new study drug, in adults with advanced solid tumors that can’t be removed and for which standard treatment has stopped working. It aims to find out how safe it is and whether it can shrink or control the cancer.
This trial tests a new drug called DB-1419 for people with advanced solid tumors that have not responded to other treatments. It is designed to target a protein called B7-H3 on cancer cells, and may help shrink tumors or slow their growth.
This study tests an experimental drug called SKB571 for people with advanced solid tumors that have not responded to or stopped responding to standard treatments. The goal is to see if SKB571 is safe and to find the right dose.
Hear when a new Solid Tumor trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.